Spoštovani kupci!
Zaradi prenove spletne strani in prehoda na OJS spletna prodaja trenutno ne dela. Prosim, če sporočite, kaj bi radi kupili, na prodaja@medrazgl.si. Dopišite vaše ime in priimek, naslov ter način plačila (s predračunom, ob povzetju ali z gotovino, če prezvamete gradivo v živo v prostorih uredištva v času uradnih ur).
Hvala za razumevanje!
MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2011 » 3 » | Archive » Medical field » Fields » Psychiatry »

Is the Use of Cognitive Modulators Reasonable in Treatment of Bipolar Mood Disorder?

 
Abstract:

This post is also available in: English Slovenščina (Slovenian)

A significant proportion of patients with bipolar disorder do not respond satisfactorily to con­ventional pharmacological treatment with lithium, anticonvulsants, antipsychotics and antidepressants. Several studies point to high risk for chronic illness and relapse despite recei­ving available therapy. At this moment we do not even have a common definition for treat­ment-resistant bipolar disorder, which makes assessing the number of patients refractory to treatment very difficult. Not only resistance to treatment, but also the evidences of cogniti­ve decline in chronic patients speak for the need for complementary therapies. Cognitive modu­lators such as donepezil, galantamine, rivastigmine and memantine are drugs that are primarily used in treating various forms of dementia. This paper collects currently available data on the use of cognitive modulators as augmentation therapy of treatment-resistant bipolar disor­der and in treatment of cognitive decline in this disease. Encouraging results of studies and case reports suggest that further research into the use of cognitive modulators in bipolar mood disorder is reasonable, primarily in terms of controlled randomized double-blind studies.

Authors:
Kržišnik Julija, Dernovšek Mojca Zvezdana

Keywords:
treatment - resistant bipolar disorder, cognitive modulators, donepezil, memantine, galantamine, cognitive decline, therapeutic resistance

Cite as:
Med Razgl. 2011; 50: 307–13.

Download PDF >>
© 2024 Društvo Medicinski razgledi | Na vrh strani / To top ↑